[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619-949-3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 593, "companyOfficers": [{"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 57, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 67, "title": "President & Director", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 45, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.99, "open": 11.98, "dayLow": 10.01, "dayHigh": 12.3053, "regularMarketPreviousClose": 11.99, "regularMarketOpen": 11.98, "regularMarketDayLow": 10.01, "regularMarketDayHigh": 12.3053, "forwardPE": -22.555555, "volume": 100218, "regularMarketVolume": 100218, "averageVolume": 60703, "averageVolume10days": 58630, "averageDailyVolume10Day": 58630, "bid": 9.87, "ask": 10.3, "bidSize": 100, "askSize": 100, "marketCap": 1021688832, "fiftyTwoWeekLow": 3.15, "fiftyTwoWeekHigh": 30.4, "priceToSalesTrailing12Months": 8.831187, "fiftyDayAverage": 15.7236, "twoHundredDayAverage": 14.44755, "currency": "USD", "enterpriseValue": 862981696, "profitMargins": -0.75758004, "floatShares": 15715904, "sharesOutstanding": 85510096, "sharesShort": 169640, "sharesShortPriorMonth": 181868, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.002, "heldPercentInsiders": 0.81732005, "heldPercentInstitutions": 0.00963, "shortRatio": 2.78, "shortPercentOfFloat": 0.026500002, "impliedSharesOutstanding": 100659000, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "earningsQuarterlyGrowth": 2.357, "netIncomeToCommon": -87645000, "forwardEps": -0.45, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 7.459, "enterpriseToEbitda": 39.454, "52WeekChange": 2.0757575, "SandP52WeekChange": 0.26943922, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GYRE", "underlyingSymbol": "GYRE", "shortName": "Gyre Therapeutics, Inc.", "longName": "Gyre Therapeutics, Inc.", "firstTradeDateEpochUtc": 1144848600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fcf12068-c88b-34d0-8632-7e45e01ea8d2", "messageBoardId": "finmb_100542295", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.15, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 37352000, "totalCashPerShare": 0.437, "ebitda": 21873000, "totalDebt": 275000, "quickRatio": 2.758, "currentRatio": 3.219, "totalRevenue": 115691000, "debtToEquity": 0.31, "revenuePerShare": 1.635, "returnOnAssets": 0.11028, "returnOnEquity": -0.99091005, "operatingCashflow": 18359000, "earningsGrowth": 2.015, "revenueGrowth": 0.09, "grossMargins": 0.96119004, "ebitdaMargins": 0.18906, "operatingMargins": 0.29703, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-29"}]